After Modi biopic, Vivek Oberoi gearing up to contest from Gujarat in 2024 polls

New Delhi, Jul 6: India's COVID-19 tally neared the 7 lakh mark with 6,97,413 cases after 24,248 new cases were reported in the last 24 hours, said the Union Ministry of Health and Family Welfare.

As per the Health Ministry, there are 2,53,287 active cases in the country while 4,24,432 patients have been cured or discharged. While one patient has migrated.

425 new deaths were reported in the last 24 hours in the country due to COVID-19, taking the number of patients succumbing to the deadly virus to 19,693.

As per the Health Ministry, Maharashtra continues to be the most impacted state from the infection with 2,06,619 cases and 8,822 fatalities due to the virus. Tamil Nadu in second place has a total of 1,11,151 cases and 1,510 fatalities.

The national capital's COVID-19 cases are also nearing the 1-lakh mark with 99,444 coronavirus cases and 3,067 deaths.

The total number of samples tested up to July 5 is 99,69,662 of which 1,80,596 samples were tested yesterday, informed the Indian Council of Medical Research on Monday. 

New Delhi, May 26: As the country celebrated Eid-ul-Fitr in the testing times of coronavirus this year, megastar Shah Rukh Khan's greetings reflected of blessings from the almighty to help the countrymen sail through the tough times.

The 54-year-old actor took to Twitter to extend Eid greetings to his fans.

"May the blessings of Allah see us through these times," he wrote in the tweet.

"In the end, it's Faith that keeps us going... Eid Mubarak to all. May He shower all with love, peace and prosperity always," Khan's tweet further read.

Eid-ul-Fitr marks the conclusion of the holy month of Ramzan, which is a month of fasting and prayer for the Muslim community.

This year, Eid is being celebrated amid a nationwide lockdown imposed as a precautionary measure to contain the spread of COVID-19.

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.